• Bestha Lakshmi Kalyani
• Anumula Rama Rao
• Guddanti Hema
• Vadladi Nikhila
• Jestadi Raga Swetha

Diabetes mellitus is a chronic metabolic disorder affecting millions of people worldwide. The development and evaluation of effective anti-diabetic drugs are crucial for managing this disease. Bioequivalence studies play a significant role in assessing the comparability between different drug formulations, ensuring their safety and efficacy. These studies aim to determine the extent to which different drug formulations exhibit similar bioavailability and therapeutic effects. The selection of the rat model for these investigations is justified by its anatomical and physiological similarities to humans, making it a valuable tool for preclinical assessments. Various anti-diabetic drug classes, including biguanides, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been investigated in rat bioequivalence studies. Pharmacokinetic parameters, such as maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and area under the plasma concentration-time curve (AUC), are commonly measured to assess drug absorption, distribution, metabolism, and elimination.

Anti Diabetic, Bioequalence Studies, Examine, Glimepiride, Glybenclamide, Metformin, Branded And Government Drug.

"Comparative Bioequivalence Studies of Antidiabetic Drugs for Optimized Diabetes Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 7, page no.d470-d479, July-2023, Available :http://www.jetir.org/papers/JETIR2307361.pdf

"Comparative Bioequivalence Studies of Antidiabetic Drugs for Optimized Diabetes Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 7, page no. ppd470-d479, July-2023, Available at : http://www.jetir.org/papers/JETIR2307361.pdf